No CrossRef data available.
Article contents
Drug treatment analysis of infective endocarditis in children—a retrospective, single-centre study
Published online by Cambridge University Press: 18 August 2025
Abstract
Objective:
A retrospective analysis of paediatric infective endocarditis characterised causative pathogens, antimicrobial susceptibility patterns, and treatment outcomes to guide clinical decision-making.
Methods:
The data of patients who received infective endocarditis between 2016 and 2023 were retrospectively collected from the medical records database. The clinical characteristics, treatment plans, and pharmaceutical monitoring characteristics were analysed and summarised.
Results:
A total of 12 paediatric infective endocarditis cases were identified. Bacterial isolates included 27 Gram-positive and 1 Gram-negative strains. The most common pathogen was Staphylococcus aureus (n = 13), all methicillin-resistant Staphylococcus aureus (MRSA), followed by Abiotrophia defectiva (n = 6), Streptococcus mitis (n = 5), Streptococcus sanguinis (n = 2), Bacillus cereus (n = 1), and Klebsiella oxytoca (n = 1). Antimicrobial therapy primarily involved linezolid, vancomycin, and cephalosporin/enzyme inhibitor combinations. Cardiac glycosides were used in 10 cases, and all patients received phosphocreatine to support myocardial energy metabolism. Therapeutic drug monitoring for vancomycin was performed in 25% of cases, while no therapeutic drug monitoring was conducted for meropenem or linezolid.
Conclusion:
All the causative organisms were predominantly Gram-positive cocci, with MRSA accounting for the largest proportion; different streptococci varied considerably in terms of drug resistance. The antimicrobial drugs used were predominantly linezolid and glycopeptides. The rate of blood concentration monitoring was low.
Keywords
Information
- Type
- Original Article
- Information
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press
Footnotes
*
These authors contributed equally to this work.
References
Sharland, M, Butler, K, Cant, A. et al. Manual of Childhood Infections: The Blue Book, 4th ed. Oxford University Press, Oxford, 2016.Google Scholar
Bin Abdulhak, AA, Baddour, LM, Erwin, P.J et al. Global and regional burden of infective endocarditis, 1990–2010: a systematic review of the literature. Glob Heart 2014; 9: 131–143. doi: 10.1016/j.gheart.2014.01.002.CrossRefGoogle ScholarPubMed
Mahony, M, Lean, D, Pham, L et al. Infective Endocarditis in Children in Queensland, Australia: Epidemiology, Clinical Features and Outcome. PEDIATR INFECT DIS J 2021; 40: 617–622. doi: 10.1097/INF.0000000000003110.CrossRefGoogle ScholarPubMed
Vicent, L, GOENAGA, MA, Muñoz, P et al. Infective endocarditis in children and adolescents: a different profile with clinical implications. PEDIATR RES 2022; 92: 1400–1406. doi: 10.1038/s41390-022-01959-3.CrossRefGoogle ScholarPubMed
Yilmaz, M, Gürses, D, Kahraman, Ö. The incidence and clinical characteristics of infective endocarditis in children: a five-year, single-centre retrospective evaluation. Cureus 2022; 14: e31747. doi: 10.7759/cureus.31747.Google ScholarPubMed
Zerhoudi, R, Karmi, S, Eljamili, M et al. Infectious endocarditis in children: epidemiological, clinical, paraclinical and therapeutic profile. SAS J Med 2023; 8: 674–685. doi: 10.36347/sasjm.2022.v08i10.003.CrossRefGoogle Scholar
Becher, P.M, Gossling, A, Fluschnik, N et al. Temporal trends in incidence, patient characteristics, microbiology and in-hospital mortality in patients with infective endocarditis: a contemporary analysis of 86,469 cases between 2007 and 2019. Clin Res Cardiol 2022; 113: 205–215. doi: 10.1007/s00392-022-02100-4.CrossRefGoogle Scholar
David, NG, Henry, F et al. The Sanford Guide to Antimicrobial Therapy 2020, (50th Editon)[M]. Peking Union Medical College Press, Beijing, 2021, 11.Google Scholar
Ferrieri, P, Gewitz, M, Gerber, M et al. Unique features of infective endocarditis in childhood. Circulation 2002; 105: 2115–2126.CrossRefGoogle ScholarPubMed
Yagupsky, P. Kingella kingae: carriage, transmission, and disease. Clin Microbiol Rev 2015; 28: 54–79.CrossRefGoogle Scholar
Cardiovascular Group. Society of pediatrics, chinese medical, association, etal, recommendation for diagnostic criteria for infectious endocarditis in children. Chin J Pediatr 2010; 48: 913–915. doi: 10.3760/cma.j.issn.0578-1310.2010.12.008.Google Scholar
Habib, G, Lancellotti, P, Antunes, MJ et al. ESC guidelines for the management of infective endocarditis. Russ J Cardiol 2016; 5: 65–116. doi: 10.15829/1560-4071-2016-5-65-116.CrossRefGoogle Scholar
Lamas, C. Infective endocarditis: comments on the 2023 Duke-international society for cardiovascular infectious diseases criteria for infective endocarditis: updating the modified Duke criteria. HVT 2023; 8: Issue 1. doi: 10.24969/hvt.2024.460.Google Scholar
National Antimicrobial Therapy Guidelines. Expert Committee on Rational Use of Medicines of the National Health and Health Commission. Peoples Medical Publishing House, Beijing, 2023. 32–33.Google Scholar
Baltimore, RS, Gewitz, M, Baddour, LM et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American heart association. Circulation 2015; 132: 1487–1515.CrossRefGoogle ScholarPubMed
Thoresen, T, Jordal, S, Lie, SA et al. Infective endocarditis: association between origin of causing bacteria and findings during oral infection screening. BMC Oral Health 2022; 22: 491. doi: 10.1186/s12903-022-02509-3.CrossRefGoogle ScholarPubMed
Pernow, G, Shannon, O, Öberg, J et al. Platelet activation and aggregation induced by streptococcus bovis/Streptococcus equinus complex. Microbiol Spectr 2022; 10: e0186122. doi: 10.1128/spectrum.01861-22.CrossRefGoogle ScholarPubMed
Ikeda, M, Yagihara, Y, Tatsuno, K et al. Clinical characteristics and antimicrobial susceptibility of bacillus cereus blood stream infections. Ann Clin Microbiol Antimicrob 2015; 14: 43.CrossRefGoogle ScholarPubMed
Steen, MK, Bruno-Murtha, LA, Chaux, G et al. Bacillus cereus endocarditis: report of a case and review. Clin Infect Dis 1992; 14: 945–946.CrossRefGoogle Scholar
Gopinathan, A, Kumar, A, Sen, AC et al. A case series and review of bacillus cereus endocarditis from India. Open Microbiol J 2018; 12: 28–33.CrossRefGoogle ScholarPubMed
Lancaster, I, Patel, D, Tamboli, C et al. Abiotrophia defectiva infective endocarditis: a rare and dangerous cause of endocarditis. Case Rep Infect Dis 2022; 2022: 7050257.Google ScholarPubMed
Rudrappa, M, Kokatnur, L Infective endocarditis due to abiotrophia defectiva and its feared complications in an immunocompetent person: rare, but real. J Glob Infect Dis 2017; 9: 79–81.CrossRefGoogle Scholar
Kiernan, TJ, O'FLAHERTY, N, Gilmore, R et al. Abiotrophia defectiva endocarditis and associated hemophagocytic syndrome-a first case report and review of the literature. Int J Infect Dis 2008; 12: 478–482.CrossRefGoogle ScholarPubMed
Tuohy, MJ, Procop, GW, Washington, JA. Antimicrobial susceptibility of abiotrophia adiacens and abiotrophia defectiva. Diagn Microbiol Infect Dis 2000; 38: 189–191.CrossRefGoogle ScholarPubMed
Zheng, X, Freeman, AF, Villafranca, J et al. Antimicrobial susceptibilities of invasive pediatric abiotrophia and granulicatella isolates. J Clin Microbiol 2004; 42: 4323–4326.CrossRefGoogle ScholarPubMed
Liao, C, Teng, LJ, Hsueh, PR et al. Nutritionally variant streptococcal infections at a University hospital in Taiwan: disease emergence and high prevalence of β-lactam and macrolide resistance. Clin Infect Dis 2004; 38: 452–455.CrossRefGoogle Scholar
Alberti, M.O, Hindler, JA, Humphries, RM. Antimicrobial susceptibilities of abiotrophia defectiva, granulicatella adiacens, and granulicatella elegans. Antimicrob Agents Chemother 2015; 60: 1411–1420.CrossRefGoogle ScholarPubMed
Cochicho Ramalho, A, Marques Santos, S, Abecasis, J et al. Abiotrophia defectiva endocarditis: a rare cause with aggressive systemic embolisation and need of valve replacement. Eur J Case Rep Intern Med 2023; 10: 003702. doi: 10.12890/2023_003702.Google ScholarPubMed
Del Franco, A, Ambrosio, G, Baroncelli, L et al. Creatine deficiency and heart failure. Heart fail rev 2022; 27: 1605–1616. doi: 10.1007/s10741-021-10173-y.CrossRefGoogle ScholarPubMed
Chen, L.H. Therapeutic effect of phosphocreatine on heart function and plasma BNP level in patients with chronic heart failure. Chin J Pract Med 2015; 42: 78–80. doi: 10.3760/cma.j.issn.1674-4756.2015.08.037.Google Scholar
Gaddi, AV, Galuppo, P, Yang, J. Creatine phosphate administration in cell energy impairment conditions: a summary of past and present research. Heart Lung Circ 2017; 26: 1026–1035. doi: 10.1016/j.hlc.2016.12.020.CrossRefGoogle ScholarPubMed
Tereshchenko, SN, Cheremisina, IA, Safiullina, AA. The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. Terapevt arkh 2022; 94: 517–523. doi: 10.26442/00403660.2022.04.201450.CrossRefGoogle Scholar
China Geriatrics Society Electrocardiograph and Cardiac Function Branch. Chinese medical doctor association cardiovascular internal medicine branch. Expert committee of chinese heart failure center alliance. Chinese expert consensus on clinical application of drugs to improve cardiac metabolism(2021). Chin J Geriatr 2021; 40: 1081–1092. doi: 10.3760/cma.j.issn.0254-9026.2021.09.001.Google Scholar
Subspecialty Group of, Cardiology, etal. Recommendations for diagnosis and treatment of heart failure in children (2020 revised edition). Zhonghua Er Ke Za Zhi 2021; 59: 84–94. doi: 10.3760/cma.j.cn112140-20200619-00737.Google Scholar
Zhuang, W, He, T, Jia, BB et al. Interaction between chinese medicine and digoxin: clinical and research update. Front Pharmacol 2023; 14: 1040778. doi: 10.3389/fphar.2023.1040778.CrossRefGoogle ScholarPubMed
Yang, JF, Wang, H, Chai, K. Highlights of the guidelines for diagnosis and treatment of heart failure in China in 2018. Chin J Cardiovasc Res 2018; 16: 1057–1060. doi: 10.3969/j.issn.Google Scholar
Albano, C, Bagarello, S, Giordano, S et al. Granulicatella spp., a Causative agent of infective endocarditis in children pathogens. Pathogens 2022; 11: 1431. doi: 10.3390/pathogens11121431.CrossRefGoogle Scholar
Fortini, MB, Mcneil, JC. HACEK infective endocarditis at a tertiary childrens hospital. J Pediatr 2021; 235: 284–287. doi: 10.1016/j.jpeds.2021.05.011.CrossRefGoogle Scholar
Editorial Board of Chinese Journal of Infectious Diseases. Editorial board of chinese journal of infectious diseases. Clinical practice expert consensus for the application of metagenomic next generation sequencing. 2020; 38: 681–689. doi: 10.3760/cma.j.cn311365-20200731-00732.CrossRefGoogle Scholar
Broom, J, Broom, A, Adams, K et al. What prevents the intravenous to oral antibiotic switch? A qualitative study of hospital doctors accounts of what influences their clinical practice. J Antimicrob Chemother 2016; 71: 2295e9. doi: 10.1093/jac/dkw129.CrossRefGoogle ScholarPubMed
Linde, K, Fassler, M, Meissner, K. Placebo interventions, placebo effects and clinical practice. Philos Trans R Soc Lond B Biol Sci 2011; 366: 1905e12. doi: 10.1098/rstb.2010.0383.CrossRefGoogle ScholarPubMed
Phillips, MC, Wald-Dickler, N, Davar, K et al. Choosing patients over placebos: oral transitional therapy vs. IV-only therapy for bacteraemia and infective endocarditis. Clin microbiol infec 2023; 29: 1126–1132. doi: 10.1016/j.cmi.2023.04.030.CrossRefGoogle ScholarPubMed
Bock, M, Theut, AM, Van Hasselt, JGC et al. Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. Clin infect dis 2023; 77: 242–251. doi:10.1093/cid/ciad168.CrossRefGoogle ScholarPubMed